Skip to main content
. 2011 Jun 15;7(3):282–292. doi: 10.5664/JCSM.1074

Figure 5.

Figure 5

Proportion of subjects reporting no RLS symptoms at Baseline and Week 12 (mITT Population)

Assessed during the 24 hours prior to baseline and Week 12 visits. aCombined treatment groups. GEn, gabapentin enacarbil; mITT, modified intent-to-treat.